October 18, 2017 05:45 PM EDTUpdated October 19, 06:09 AM

FDA follows through with a groundbreaking OK for Yescarta, Gilead's new CAR-T breakthrough

John Carroll

Editor & Founder

Just two weeks after Gilead closed on its $12 billion Kite buyout, the FDA has followed through with a groundbreaking approval of Yescarta (axi-cel), putting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA follows through with a groundbreaking OK for Yescarta, Gilead's new CAR-T breakthrough

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Summit’s disappointing survival readout raises stakes for full data

Summit says bispecific misses overall survival in closely-watched lung cancer study

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

As a challenging first half nears a close, biopharma uncertainty persists

Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop

From weeks to days: how Aizon Intelligent Agents transform pharma validation

FDA fol­lows through with a ground­break­ing OK for Yescar­ta, Gilead­'s new CAR-T break­through

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA follows through with a groundbreaking OK for Yescarta, Gilead's new CAR-T breakthrough